Strateos Closes $ 56 Million Series B Funding to Accelerate Deployment of its SmartLab of the Future Platform
New funding led by DCVC and Lux Capital will expand next generation of smart lab solutions with direct access to automation to accelerate discovery in life sciences
Strateos, Inc., a pioneer in the development of remote access labs and lab control software for life science research, today announced the closing of its 56.1 Series B funding. million dollars led by DCVC and Lux Capital with the participation of new investors including Eli Lilly and Company, Ally Bridge Group, Black Diamond Ventures, Mack & Co., LLC and Castor Ventures. With this funding, Strateos will continue to innovate on its SmartLab Platform ™, which integrates data generation and AI activation with its unique and flexible automation to accelerate R&D in pharmaceutical and synthetic biology.
“Life sciences research needs faster, more reliable and lower cost data to take full advantage of artificial intelligence-based analysis tools,” said Mark Fischer-Colbrie, CEO of Strateos. “Our unique fleet of laboratory automation modules, accessible from anywhere in the world, accelerates the design-manufacture-test-analysis cycle and generates clean, AI-enabled data. Strateos is pleased to have the support of these world class modules. investors who bring deep expertise in building and scaling innovative platforms at the intersection of life sciences and information technology. With their support, Strateos is reinventing the world of life science research and ushering in a new era of decentralized discovery.
Strateos leverages the resources of the company’s two SmartLab studios in Menlo Park and San Diego, Calif., Which together represent over 14,000 square feet of lab space and over 200 cutting-edge research instruments tailored to the needs. application of small – the discovery of molecules and biological drugs, cell and gene therapies and synthetic biology. These secure, remote-controlled laboratories are accessed through sophisticated command and control tools that allow scientists to design, manage, and collaborate on scientific workflows that deliver high-quality data that can be easily analyzed and shared. Strateos life sciences customers are also leveraging Command & Control software to improve their internal operations and laboratory facilities locally and globally.
“The Strateos team has truly built the lab of the future and frees scientists from the limitations of their location or lack of access to automation by creating a direct path to smart labs,” said Josh Wolfe, Co-Founder and Partner director of Lux Capital. “Data is the most important resource in scientific discovery and laboratory redesign, as quality-driven data centers will help the life sciences industry take advantage of this valuable asset. We are delighted to partner with the forward-looking team at Strateos and join them in their mission to help change the pace of life science discovery for the benefit of all. “
Strateos is a pioneer in the development of remote access labs and lab control software for life science discovery. Our mission is to create new knowledge driven by data, computation, automation and high throughput robotics with the aim of fundamentally advancing the life sciences. The Strateos SmartLab Platform ™ helps scientists design, run and analyze experiments more efficiently and reproducibly to make new scientific discoveries faster. For more information, please visit www.strateos.com.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20210608005436/en/